(-0.16%) 5 460.42 points
(-0.36%) 38 972 points
(0.19%) 17 751 points
(0.41%) $81.16
(-3.48%) $2.66
(-0.94%) $2 309.00
(-0.37%) $28.76
(1.34%) $999.60
(0.23%) $0.935
(0.83%) $10.69
(0.35%) $0.791
(-0.28%) $87.24
Live Chart Being Loaded With Signals
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States...
Stats | |
---|---|
本日の出来高 | 31 317 |
平均出来高 | 0 |
時価総額 | 7.08M |
EPS | $-0.430 ( Q2 | 2022-08-12 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.60 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.366 (15.57%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-05-17 | Hardy Reginald L | Buy | 65 000 | Stock Option (right to buy) |
2022-05-17 | Hardy Reginald L | Buy | 65 000 | Stock Option (right to buy) |
2022-05-17 | Samant Vijay B | Buy | 65 000 | Stock Option (right to buy) |
2022-05-17 | Lyons Gary A | Buy | 65 000 | Stock Option (right to buy) |
2022-05-17 | Lyons Gary A | Buy | 65 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
0.00 |
Last 98 transactions |
Buy: 10 056 470 | Sell: 193 721 |
ボリューム 相関
Brickell Biotech, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Brickell Biotech, Inc. 相関 - 通貨/商品
Brickell Biotech, Inc. 財務諸表
Annual | 2021 |
収益: | $404 000 |
総利益: | $0.00 (0.00 %) |
EPS: | $-22.05 |
FY | 2021 |
収益: | $404 000 |
総利益: | $0.00 (0.00 %) |
EPS: | $-22.05 |
FY | 2020 |
収益: | $1.82M |
総利益: | $0.00 (0.00 %) |
EPS: | $-38.25 |
FY | 2019 |
収益: | $7.92M |
総利益: | $0.00 (0.00 %) |
EPS: | $-202.50 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Brickell Biotech, Inc.
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。